Navigation Links
Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma
Date:6/22/2011

VIENNA, June 22, 2011 /PRNewswire/ --


 

Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). It is presently under investigation in a phase III trial across various European clinical centers. In return, Apeiron obtains the rights to file for regulatory approval and to market the final product. The approach is based on a monoclonal antibody (ch14.18) and constitutes Apeiron's most advanced project. It also marks another milestone for the company and its development strategy to treat neuroblastoma. This strategy was initiated earlier this year with the licensing of a clinical phase II project from Merck KGaA.

Today, Vienna based Apeiron announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

The Austrian company Polymun Scientific, a long-time business partner of Apeiron, has already been producing clinical supplies for the CCRI/SIOPEN sponsored clinical studies. Apeiron has now commissioned Polymun to continue production and to prepare for manufacture of material at market standard.

Dr. Hans Loibner, CEO of Apeiron: „This novel form of collaboration with CCRI and SIOPEN is a milestone for Apeiron. These non-profit organizations have accomplished remarkable clinical development achievements which we can now complement with our industrial know-how. With this collaboration, we add a project to our portfolio that is both innovative and close to the market."

Professor Ruth Ladenstein, head of the coordination center for clinical studies at CCRI, senior physician at St. Anna Kinderspital and European president of SIOP: „We are convinced to have found an ideal partner in Apeiron. Together, we will take the final steps of development for an urgently needed therapy against high-risk neuroblastoma. By applying immune therapy and other treatment improvements, we hope to increase the chances of survival for children with high-risk neuroblastoma by 30%, thereby rendering future survival rates of 60-70% realistic."

Financial details were not disclosed.

Jacqueline Bogdanovic
+43-1-505-70-44
bogdanovic@prd.at
[contact@prd.at ]
http://http://www.prd.at



'/>"/>
SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
2. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
3. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
6. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
7. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
8. Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
10. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
11. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):